Filing Flows › Comparisons › OMER vs ZNTL
Omeros vs Zentalis Pharmaceuticals: OMER and ZNTL compared
Omeros is the larger company: $28.5M of revenue in its latest quarter (Q2 2026) against $26.9M for Zentalis Pharmaceuticals (Q4 2024). Omeros is more profitable, with an operating margin of 0.3% against -185.6%.
Where the money goes: OMER and ZNTL
Omeros (OMER) · Q2 2026
Omeros, Q2 2026: revenue $28.5M, operating margin 0.3%, net earnings $13.2M, operating cash flow $4.1M. The chart follows the revenue to costs, profit and cash.
Zentalis Pharmaceuticals (ZNTL) · Q4 2024
Zentalis Pharmaceuticals, Q4 2024: revenue $26.9M, operating margin -185.6%, net loss $47.5M, operating cash flow −$39.7M. The chart follows the revenue to costs, profit and cash.
| Omeros (OMER) | Zentalis Pharmaceuticals (ZNTL) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q4 2024 |
| Revenue | $28.5M | $26.9M |
| Operating margin | 0.3% | -185.6% |
| Net earnings | $13.2M | −$47.5M |
| Net margin | 46.4% | -176.7% |
| Operating cash flow | $4.1M | −$39.7M |
| Free cash flow | $4.1M | — |
| Market value | $1.8B | — |
| P/E | 14.4× | — |
| Analysts’ mean target | $27.50 | — |
Questions
Which is bigger, Omeros or Zentalis Pharmaceuticals?
Omeros is the larger company: $28.5M of revenue in its latest quarter (Q2 2026) against $26.9M for Zentalis Pharmaceuticals (Q4 2024).
Is Omeros or Zentalis Pharmaceuticals growing faster?
Omeros is more profitable, with an operating margin of 0.3% against -185.6%.
More: Omeros earnings · how Omeros makes money · Zentalis Pharmaceuticals earnings · how Zentalis Pharmaceuticals makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 12, 2026; 10-K filed Mar 26, 2025). Fiscal quarters can end on different dates. Not investment advice.